Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Operating expenses: | |||
| Research and development | $456,660 | $360,917 | $212,928 |
| Acquired in-process research and development | — | — | 12,500 |
| General and administrative | 76,242 | 77,235 | 57,281 |
| Total operating expenses | 532,902 | 438,152 | 282,709 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other (income) expense, net | (2,181) | (471) | 1,008 |
| Loss before provision for income taxes | (505,391) | (412,949) | (258,769) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s R&D?
- Immunovant, Inc. (IMVT) reported R&D of $142.29M in Q1 2026.
- How has Immunovant, Inc.'s R&D changed year-over-year?
- Immunovant, Inc.'s R&D increased by 51.9% year-over-year, from $93.65M to $142.29M.
- What is the long-term trend for Immunovant, Inc.'s R&D?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s R&D has grown at a 45.5% compound annual growth rate (CAGR), from $101.81M to $456.66M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Immunovant, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude